晨光生物：关于转让控股子公司股权的进展公告

Core Viewpoint - The company announced the transfer of 97.5% equity in Hebei Chenguang Tongsheng Pharmaceutical Co., Ltd. to Sichuan Tongsheng Biopharmaceutical Co., Ltd. for a price of 58.2347 million yuan, resulting in the former no longer being a subsidiary within the company's consolidated financial statements [2]. Group 1 - The board of directors approved the proposal for the equity transfer during the 19th meeting of the fifth session held on September 20, 2025 [2]. - The equity transfer has been completed with the necessary business registration changes and the issuance of a registration notice by the Hebei Guantao Economic Development Zone [2]. - Following the completion of this transfer, Chenguang Pharmaceutical will no longer hold any equity in Chenguang Tongsheng Pharmaceutical [2].